COVID-19 Notice: We are providing FREE consultations via phone or video conferencing for your safety and convenience. Learn More »
Published on:

Drug Blog Round-Up

Not drug-related, but Happy Anniversary is in order.
Now that you know more about me than you are probably comfortable with (who celebrates that?), let’s get to business with some noteworthy items:

  • Reuters discusses the FDA’s investigation of using drugs like Seroquel on children.
  • Recently expanded indications for Seroquel by children.
  • The Chicago Tribune writes about abuses in prescribing psychotropic medications without consent and without a valid medical reason. Note the front-and-center picture of Seroquel.
  • The Wall Street Journal discusses a clinical study showing that an experimental once-a-week treatment works better to treat type-2 diabetes than Januvia.
  • Tomorrow (December 8, 2009) the FDA will convene a joint meeting of the Cardiovascular and Renal Drugs Committee and Drug Safety and Risk Management Advisory Committee. They will discuss safety as it pertains to Gadolinium-based contrast agents, which are used before MRI procedures. A copy of the background material (agenda, briefing information, and meeting roster) is located here. More information on Gadolinium-based contrast agents can be found at our blog and our website.
  • More on Ghostwriting (courtesy Brian Ketterer). I like this excerpt:

If a professional writer is paid by a company to write a piece and a non-author doctor is asked to approve it, the appropriate outcome would be for the professional writer to be listed as the author and for the non-author doctor to be thanked in an acknowledgement for having reviewed the paper. If the non-author doctor makes substantial enough changes to the paper, he or she might be listed as a coauthor. In either case, the funding for the paper should be disclosed.

Happy Monday!